International Clinical and Medical Case Reports Journal (ISSN: 2832-5788) | Volume 3, Issue 2 | Case Report | Open Access DOI
Mahvish Renzu*
Mahvish Renzu MD1*, Vidhi Mehta MD2, Shrikanth Sampath MD3, Adam Manzoor Qazi MD4, Durga K. Yerasuri MD4
1Internal Medicine, Trinity Health Oakland, Pontiac, MI
2Internal Medicine, Mercy Fitzgerald Hospital, Upper Darby, PA
3Internal Medicine, Wayne State University, Detroit, MI
4Internal Medicine, Trinity Health Livonia Hospital, MI
*Correspondence to: Mahvish Renzu
Fulltext PDFTenofovir Disoproxil Fumarate (TDF) is one of the drugs in the initial first-line antiretroviral regimen for the treatment of HIV infections with a rare side effect of bone toxicity. We describe a case of an HIV-positive man who had been using TDF for 9 years and had presented to the emergency room with multiple fractures. The bone fracture investigation identified reduced bone mineral density and severe osteoporosis. TDF was discontinued, and treatment was focused on controlling the bone disease through vitamin D and calcium supplementation. After the new treatment regimen, the patient exhibited a slow improvement in his bone mass density (BMD). Long-term follow-up is still required to assess subsequent changes in BMD and fracture healing. This abstract provides a concise overview of the mechanisms underlying tenofovir-induced bone loss and highlights current management strategies.
Tenofovir Disoproxil Fumarate; Drugs; HIV
Mahvish Renzu, Vidhi Mehta, Shrikanth Sampath, Adam Manzoor Qazi, Durga K. Yerasuri. Navigating Tenofovir-Associated Osteoporosis: Lessons from a Case Study. Int Clinc Med Case Rep Jour. 2024;3(2):1-3.